This filing is a routine corporate presentation update with no new material financial disclosures. Monitor upcoming regulatory catalysts (pivotal trial initiation for VMT-α-NET, further ASCO data) for tangible valuation events. No immediate trading action warranted.
Price Chart
Executive Summary
Perspective Therapeutics updated its corporate presentation on June 1, 2026, highlighting ASCO 2026 data for its 212Pb-based radiopharmaceutical pipeline. The filing is a routine update of investor materials with no new material financial information or definitive clinical results.
Key Facts
- Perspective Therapeutics filed a corporate presentation as Exhibit 99.1 on June 1, 2026.
- Presentation highlights ongoing Phase 1/2a trials for VMT-α-NET (SSTR2+ NETs), VMT01 (MC1R melanoma), and PSV359 (FAP-α solid tumors).
- ASCO 2026 data analysis shows 'durable disease control' and 'best-in-class safety profile' for VMT-α-NET with n=68 patients.
- No financial results, guidance, or material definitive agreements were disclosed in this filing.
Financial Impact
No financial figures provided in the filing; pre-revenue clinical-stage biotech with no disclosed material financial impact.
Risk Factors
- Clinical-stage biotech with no approved products; regulatory and clinical execution risk.
- No revenue or profitability; reliance on capital markets for funding.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-249594 |
| Document: catx-ex99_1.htm | 0001193125-26-249594 |
| Document: 0001193125-26-249594-index-headers.html | 0001193125-26-249594 |
| Document: 0001193125-26-249594-index.html | 0001193125-26-249594 |
| Document: 0001193125-26-249594.txt | 0001193125-26-249594 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $1.61 | awaiting T+20 | — | $1.21 (−24.84%) |
Oct 8, 2026 18d ago | 8-K | $2.71 | awaiting T+20 | — | $1.21 (−55.35%) |
Oct 2, 2026 24d ago | Press Release | $2.76 | awaiting T+20 | — | $1.21 (−56.16%) |
Sep 14, 2026 6w ago | 8-K | $2.92 $2.52 | ▼ −13.70% | ▼ −15.96% | $1.21 (−58.56%) |
Sep 11, 2026 6w ago | Press Release | $2.81 $2.66 | ▼ −5.34% | ▼ −7.21% | $1.21 (−56.94%) |
Sep 8, 2026 6w ago | Insider Cluster | $2.99 $2.46 | ▼ −17.73% | ▼ −19.67% | $1.21 (−59.53%) |
Sep 4, 2026 7w ago | Insider Cluster | $3.12 $2.36 | ▼ −24.36% | ▼ −26.07% | $1.21 (−61.22%) |
Sep 4, 2026 7w ago | Insider Cluster | $3.12 $2.36 | ▼ −24.36% | ▼ −26.07% | $1.21 (−61.22%) |
Aug 10, 2026 11w ago | 8-K | $3.18 $2.99 | ▼ −5.97% | ▼ −4.92% | $1.21 (−61.95%) |
Jul 17, 2026 14w ago | Press Release | $2.99 $3.20 | ▲ +7.02% | ▲ +2.58% | $1.21 (−59.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers